United States - English - NLM (National Library of Medicine)

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify (aripiprazole) oral tablets, orally-disintegrating tablets, and oral solution are indicated for the treatment of: - schizophrenia - acute treatment of manic and mixed episodes associated with bipolar i disorder - adjunctive treatment of major depressive disorder - irritability associated with autistic disorder - treatment of tourette's disorder abilify injection is indicated for the treatment of: - agitation associated with schizophrenia or bipolar mania abilify is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including abilify, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhea

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - aripiprazole - tablet - 15mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole 15mg;   - tablet - 15 mg - active: aripiprazole 15mg   excipient: hyprolose iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - abilify is indicated of the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; hyprolose; iron oxide yellow; maize starch; microcrystalline cellulose; lactose monohydrate - - abilify is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy. - acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate; - maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see clinical studies (14.1)] . acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults [see clinical studies (14.2)] . maintenance treatment of bipolar i disorder abilify is indicated for the maintenance treatment of bipolar i disorder, both as monotherapy and as an adjunct to either lithium or valproate. maintenance efficacy was

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

otsuka pharmaceuticals (u.k. - aripiprazole - orodispersible tablet - 15mg

European Union - English - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.abilify is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.

Israel - English - Ministry of Health

bristol-myers squibb (israel) limited - aripiprazole 15 mg - tablets - aripiprazole - abilify is indicated for the treatment of schizophrenia. and for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - abilify is indicated for the treatment of schizophrenia. the efficacy of abilify was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents . [see clinical studies ] (14.1) acute treatment of manic and mixed episodes abilify is indicated for the acute treatment of manic and mixed episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or valproate. efficacy as monotherapy was established in four 3-week monotherapy trials in adults and one 4-week monotherapy trial in pediatric patients (10 to 17 years). efficacy as adjunctive therapy was established in one 6-week adjunctive trial in adults . [see clinical studies ] (14.2) maintenance treatment of bipolar i disorder abilify is indic